Who are Olanzapine, risperidone's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Risperidone and placebo comparator, Risperdal Consta (drug), Zyprexa® (OLANZapine 5MG), bifeprunox, olanzapine, Rapid Acting Intramuscular Olanzapine, Risperidone, oral tablets.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/olanzapine-risperidone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Olanzapine, risperidone — Competitive Intelligence Brief

Olanzapine, risperidone (Olanzapine, risperidone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: atypical antipsychotic. Area: Psychiatry.

phase 3 atypical antipsychotic D2 receptor, 5-HT2A receptor Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

Olanzapine, risperidone (Olanzapine, risperidone) — AstraZeneca. Olanzapine and risperidone are atypical antipsychotics that work by blocking dopamine and serotonin receptors in the brain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Olanzapine, risperidone TARGET	Olanzapine, risperidone	AstraZeneca	phase 3	atypical antipsychotic	D2 receptor, 5-HT2A receptor
Risperidone and placebo comparator	Risperidone and placebo comparator	University of Alabama at Birmingham	phase 3	atypical antipsychotic	D2 receptor, 5-HT2A receptor
Risperdal Consta (drug)	Risperdal Consta (drug)	University of Illinois at Chicago	phase 3	Atypical antipsychotic	D2 receptor, 5-HT2A receptor
Zyprexa® (OLANZapine 5MG)	Zyprexa® (OLANZapine 5MG)	CR-CSSS Champlain-Charles-Le Moyne	phase 3	atypical antipsychotic	D2 receptor, 5-HT2A receptor
bifeprunox, olanzapine	bifeprunox, olanzapine	Wyeth is now a wholly owned subsidiary of Pfizer	phase 3	Atypical antipsychotic	D2 receptor, 5-HT2A receptor
Rapid Acting Intramuscular Olanzapine	Rapid Acting Intramuscular Olanzapine	Eli Lilly and Company	phase 3	atypical antipsychotic	D2 receptor, 5-HT2A receptor
Risperidone, oral tablets	Risperidone, oral tablets	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	phase 3	atypical antipsychotic	D2 receptor, 5-HT2A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (atypical antipsychotic class)

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 2 drugs in this class
AstraZeneca · 2 drugs in this class
Eli Lilly and Company · 1 drug in this class
University of Alabama at Birmingham · 1 drug in this class
Qilu Pharmaceutical Co., Ltd. · 1 drug in this class
Sumitomo Pharma Co., Ltd. · 1 drug in this class
CR-CSSS Champlain-Charles-Le Moyne · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Olanzapine, risperidone — Competitive Intelligence Brief. https://druglandscape.com/ci/olanzapine-risperidone. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab